This trial is testing a new cancer drug, ENB003, to see if it is safe and effective. The study will first test the drug on a small group of people to see what doses are safe. Then the study will be expanded to include more people with different types of cancer.
2 Primary · 8 Secondary · Reporting Duration: up to 2 years while subjects remain in the study
130 Total Participants · 6 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 1 & 2
Age 18 - 80 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: